Most weight-loss jabs users are at risk of putting the pounds back on because they quit within a year, a new study has found.

Microdosing weight loss drugs, a growing global trend, could offer a new gateway solution for obesity for those priced out of ...

"For them to work effectively, they need to be taken long term," cautioned epidemiologisy professor Reimar W. Thomsen.

Surveys show that nearly 12% of Americans have turned to Ozempic, Wegovy or similar drugs to lose weight, with prescriptions more than tripling since 2020. But new research suggests many users are ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat ...

Nordisk and Eli Lilly are set to reshape the oral GLP-1 market as patient demand grows and new therapies emerge. Learn more ...

Novo Nordisk leads globally in GLP-1s despite U.S. pressure, with a strong pipeline, cost cuts, and attractive valuation.

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists like Ozempic®, Wegovy®, Mounjaro®, and Zepbound®. While Ozempic can be ...

"I'm upping my dose a little because I want to be extra-snatched," the model said of her Maxim shoot in a clip from her ...

State agencies, including Boise State, were recently notified that the State of Idaho will eliminate insurance coverage for ...

Novo Nordisk will lay off 9,000 employees worldwide as part of a restructuring plan, redirecting savings to diabetes and obesity drug growth.

The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for ...